For patients with advanced HER2(+) breast cancer progressing with therapy with anthracyclines, taxanes, and trastuzumab, it is recommended to administer 1,250 mg of lapatinib in combination with capecitabine (4). Here, ERBB2 is linked to breast carcinoma.